

December 27, 1968

Dr. William Tabor
A.H. Robins Co.
1407 Cummings
Richmond, Va. 23220

Dear Bill,

Enclosed are the corrected butaperazine report forms. The principal difficulty lies in our interpretation of the item 15 and in the lack of discrimination among psychiatric diagnoses.

We had interpreted the item 15 as a sampling of the dosage periods. The maximum dosage achieved was only occasionally the maintenance dosage; more usually, the maintenance dosage was somewhat less. The report shows the largest period of sustained drug effect. On each, however, we have indicated the maximum dose as well.

Also, the date stopped was interpreted as the date of the end of the report period. In some instances, patients continued beyond the report period. This was occasionally noted on the summary (narrative) which was written after the summary (report form) was completed.

Diagnoses are all variations of schizophrenia. In some instances, the depressive component was given credit in the narrative summary, although chronic schizophrenia was the principal diagnosis. The use of catatonic, paranoid or simple subtypes was additive; and chronic schizophrenia is the principal diagnosis.

I trust these corrections clarify the questions. Thank you for bringing these discrepancies to our attention.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

mf/